Literature DB >> 820717

Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin.

J E Gerich, M Lorenzi, D M Bier, E Tsalikian, V Schneider, J H Karam, P H Forsham.   

Abstract

To study the individual effects of glucagon and growth hormone on human carbohydrate and lipid metabolism, endogenous secretion of both hormones was simultaneously suppressed with somatostatin and physiologic circulating levels of one or the other hormone were reproduced by exogenous infusion. The interaction of these hormones with insulin was evaluated by performing these studies in juvenile-onset, insulin-deficient diabetic subjects both during infusion of insulin and after its withdrawal. Infusion of glucagon (1 ng/kg-min) during suppression of its endogenous secretion with somatostatin produced circulating hormone levels of approximately 200 pg/ml. When glucagon was infused along with insulin, plasma glucose levels rose from 94 +/- 8 to 126 +/- 12 mg/100 ml over 1 h (P less than 0.01); growth hormone, beta-hydroxy-butyrate, alanine, FFA, and glycerol levels did not change. When insulin was withdrawn, plasma glucose, beta-hydroxybutyrate, FFA, and glycerol all rose to higher levels (P less than 0.01) than those observed under similar conditions when somatostatin alone had been infused to suppress glucagon secretion. Thus, under appropriate conditions, physiologic levels of glucagon can stimulate lipolysis and cause hyperketonemia and hyperglycemia in man; insulin antagonizes the lipolytic and ketogenic effects of glucagon more effectively than the hyperglycemic effect. Infusion of growth hormone (1 mug/kg-h) during suppression of its endogenous secretion with somastostatin produced circulating hormone levels of approximately 6 ng/ml. When growth hormone was administered along with insulin, no effects were observed. After insulin was withdrawn, plasma beta-hydroxybutyrate, glycerol, and FFA all rose to higher levels (P less than 0.01) than those observed during infusion of somatostatin alone when growth hormone secretion was suppressed; no difference in plasma glucose, alanine, and glucagon levels was evident. Thus, under appropriate conditions, physiologic levels of growth hormone can augment lipolysis and ketonemia in man, but these actions are ordinarily not apparent in the presence of physiologic levels of insulin.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 820717      PMCID: PMC436731          DOI: 10.1172/JCI108364

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  48 in total

1.  Effect of growth hormone on plasma fatty acids.

Authors:  M S RABEN; C H HOLLENBERG
Journal:  J Clin Invest       Date:  1959-03       Impact factor: 14.808

2.  Elevation of plasma epinephrine levels produced by glucagon in vivo.

Authors:  E J SARCIONE; N BACK; J E SOKAL; B MEHLMAN; E KNOBLOCK
Journal:  Endocrinology       Date:  1963-04       Impact factor: 4.736

3.  Metabolic effects of glucagon in human subjects.

Authors:  J M SALTER; C EZRIN; J C LAIDLAW; A G GORNALL
Journal:  Metabolism       Date:  1960-08       Impact factor: 8.694

4.  Diabetogenic and hypoglycemic effects of human growth hormone.

Authors:  O H PEARSON; J M DOMINGUEZ; E GREENBERG; A PAZIANOS; B S RAY
Journal:  Trans Assoc Am Physicians       Date:  1960

5.  Role of lipolytic and glucocorticoid hormones in the development of diabetic ketosis.

Authors:  S S Chernick; C M Clark; R J Gardiner; R O Scow
Journal:  Diabetes       Date:  1972-09       Impact factor: 9.461

6.  Glucagon control of fasting glucose in man.

Authors:  F P Alford; S R Bloom; J D Nabarro; R Hall; G M Besser; D H Coy; A J Kastin; A V Schally
Journal:  Lancet       Date:  1974-10-26       Impact factor: 79.321

7.  Metabolic response to human growth hormone during prolonged starvation.

Authors:  P Felig; E B Marliss; G F Cahill
Journal:  J Clin Invest       Date:  1971-02       Impact factor: 14.808

8.  Effect of growth hormone and dexamethasone on lipolysis and metabolism in isolated fat cells of the rat.

Authors:  J N Fain; V P Kovacev; R O Scow
Journal:  J Biol Chem       Date:  1965-09       Impact factor: 5.157

9.  Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men.

Authors:  J E Liljenquist; J D Bomboy; S B Lewis; B C Sinclair-Smith; P W Felts; W W Lacy; O B Crofford; G W Liddle
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

10.  EFFECT OF HUMAN GROWTH HORMONE ON MUSCLE AND ADIPOSE TISSUE METABOLISM IN THE FOREARM OF MAN.

Authors:  D RABINOWITZ; G A KLASSEN; K L ZIERLER
Journal:  J Clin Invest       Date:  1965-01       Impact factor: 14.808

View more
  50 in total

1.  Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.

Authors:  A J Scheen; J Gillet; J Rosenthaler; J Guiot; P Henrivaux; B Jandrain; P J Lefèbvre
Journal:  Diabetologia       Date:  1989-11       Impact factor: 10.122

2.  Growth hormone directly favors hepatic ketogenesis in persons with prediabetes or type 2 diabetes mellitus treated with empagliflozin.

Authors:  Aline Franco da Rocha; Paulo Sergio Pereira Junior; Gabriela Simonetti Calefi; Guilherme Figueiredo Marquezine; Helena Kaminami Morimoto; Tania Longo Mazzuco; Eliana Cotta de Faria; Mariana Ragassi Urbano; Alexandre Jose Faria Carrilho
Journal:  Endocrine       Date:  2021-04-19       Impact factor: 3.633

3.  Clinical evaluation of somatostatin as a potential ajunct to insulin in the management of diabetes mellitus.

Authors:  J E Gerich; T A Schultz; S B Lewis; J H Karam
Journal:  Diabetologia       Date:  1977-09       Impact factor: 10.122

4.  Clinical evidence of growth hormone for patients undergoing abdominal surgery: meta-analysis of randomized controlled trials.

Authors:  Yong Zhou; Xiao-Ting Wu; Gang Yang; Wen Zhuang; Mao-Ling Wei
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

5.  Rates of noninsulin-mediated glucose uptake are elevated in type II diabetic subjects.

Authors:  A D Baron; O G Kolterman; J Bell; L J Mandarino; J M Olefsky
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

6.  Failure of glucagon to stimulate ketone body production during acute insulin deficiency or insulin replacement in man.

Authors:  G E Sonnenberg; W Stauffacher; U Keller
Journal:  Diabetologia       Date:  1982-08       Impact factor: 10.122

7.  Metabolic effects of acute and prolonged growth hormone excess in normal and insulin-deficient man.

Authors:  P Metcalfe; D G Johnston; R Nosadini; H Orksov; K G Alberti
Journal:  Diabetologia       Date:  1981-02       Impact factor: 10.122

8.  Insulin-like growth factor-I in man enhances lipid mobilization and oxidation induced by a growth hormone pulse.

Authors:  T L Bianda; M A Hussain; A Keller; Y Glatz; O Schmitz; J S Christiansen; K G Alberti; E R Froesch
Journal:  Diabetologia       Date:  1996-08       Impact factor: 10.122

9.  Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man.

Authors:  J E Liljenquist; G L Mueller; A D Cherrington; U Keller; J M Perry; W W Lacy; D Rabinowitz
Journal:  J Clin Invest       Date:  1977-02       Impact factor: 14.808

10.  Influence of somatostatin on splanchnic glucose metabolism in postabsorptive and 60-hour fasted humans.

Authors:  J Wahren; S Efendić; R Luft; L Hagenfeldt; O Björkman; P Felig
Journal:  J Clin Invest       Date:  1977-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.